Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Apyx Medical Corporation (APYX) delivers innovative plasma-based energy systems for surgical and cosmetic applications. This news hub provides investors and medical professionals with timely updates on regulatory developments, product innovations, and strategic partnerships driving advancements in electrosurgical technology.
Access authoritative reporting on APYX's Advanced Energy segment developments, including Renuvion® system enhancements, and OEM manufacturing collaborations. Track financial performance updates, clinical study results, and market expansion initiatives critical to evaluating the company's position in medical device innovation.
Our curated news collection features earnings announcements, FDA clearances, research publications, and executive leadership changes. Stay informed about helium plasma technology applications in dermatology and general surgery through verified sources, maintained for accuracy and relevance.
Bookmark this page for streamlined access to APYX's evolving corporate narrative. Combine real-time updates with historical context to better understand this pioneer in energy-based surgical solutions.
Apyx Medical Corporation (NASDAQ:APYX) reported a strong financial performance for Q1 2022, with total revenue of $12.5 million, marking a 45% increase year-over-year. The Advanced Energy segment contributed $10.8 million in revenue, a growth of 41%, while OEM revenue surged 72% to $1.7 million. Despite this success, the company reported a net loss of $5.9 million. The outlook for 2022 has been revised to forecast total revenue between $52.5 million and $59.0 million, reflecting growth of 8% to 22%.
Apyx Medical Corporation (NASDAQ:APYX) announced it will release its financial results for Q1 fiscal 2022 on May 12, 2022, before the market opens. Management will host a conference call at 8:00 a.m. ET on the same day to discuss these results and answer questions from investors. Interested parties can join the call by dialing a provided number and using an access code. The results will be available on the company's website.
Apyx Medical Corporation (NASDAQ:APYX) announced the submission of a 510(k) premarket notification to the FDA. This aims to expand indications for the Renuvion APR Handpiece, allowing its use in subcutaneous dermatological and aesthetic procedures to improve lax skin in the neck and submental region. CEO Charlie Goodwin highlighted that this submission aligns with their strategic long-term goals and is backed by safety and effectiveness data from a U.S. IDE clinical study. Successful FDA clearance would enhance market opportunities for Apyx's Renuvion technology.
Apyx Medical reported a strong performance in Q4 2021, with total revenue reaching $16.8 million, a 47% increase year-over-year. Advanced Energy sales surged 52% to $15.0 million, while OEM revenue rose 13% to $1.8 million. Despite a net loss of $2.0 million, improved efficiencies reduced the adjusted EBITDA loss to $0.3 million. For 2022, guidance is set between $50.0 million to $63.0 million in total revenue, indicating potential growth of 3% to 30%.
Apyx Medical Corporation (NASDAQ:APYX) announced that the FDA intends to issue a Medical Device Safety Communication (MDSC) regarding its Advanced Energy products, specifically concerning their off-label use. The company emphasizes ongoing compliance and support for safe practices, despite some products being used for unapproved dermal resurfacing. Apyx continues to work with the FDA for 510(k) clearances for additional clinical indications and maintains its existing clearances. Since 2017, 90 medical device reports (MDRs) have been submitted, although these represent a small fraction of total procedures performed.
Apyx Medical Corporation (NASDAQ:APYX) announced the submission of an FDA 510(k) premarket notification for its Renuvion® Dermal Handpiece aimed at dermatological procedures requiring ablation and resurfacing. This follows the publication of a peer-reviewed study in Lasers in Surgery and Medicine, confirming that 100% of subjects experienced an improvement in wrinkle scores after treatment. The study reports high satisfaction rates and no serious adverse events, supporting Apyx's regulatory strategy and market expansion goals in the U.S. cosmetic surgery market.
Apyx Medical Corporation (NASDAQ:APYX) is set to release its financial results for the fourth quarter and fiscal year 2021 on March 17th, before the market opening. A conference call will be held at 8:00 a.m. ET on the same day, allowing stakeholders to discuss the results and participate in a Q&A session. The call can be accessed via phone or a live webcast on the Company's website. A replay will be available until March 31, 2022.
Apyx Medical specializes in innovative medical devices, showcasing its Helium Plasma Technology.
Apyx Medical Corporation (NASDAQ:APYX) announced its preliminary revenue results for Q4 and full year 2021, revealing $16.3 to $16.8 million in Q4, a year-over-year growth of 42% to 46%.
Advanced Energy sales ranged from $14.7 to $15.0 million, indicating a 49% to 52% increase compared to last year. For the full year, total revenue reached $48.0 to $48.5 million, a growth of 73% to 75%. However, OEM revenue faced a slight decline.
CEO Charlie Goodwin highlighted strong adoption of their Renuvion® technology in the U.S., driving sales above expectations.
Apyx Medical Corporation (NASDAQ:APYX) reported strong Q3 2021 results, with total revenue reaching $11.8 million, a 70% increase year-over-year. Advanced Energy sales surged 88% to $10.3 million, driven by increased demand for Renuvion® products. Net loss attributable to stockholders was $4.2 million, slightly higher than $3.7 million in Q3 2020. Full year revenue guidance was raised to $44-45 million, reflecting a year-over-year growth of 59%-62%. As of September 30, 2021, the company held $30.9 million in cash and equivalents.
Apyx Medical Corporation (NASDAQ:APYX) announced its participation in several upcoming investor conferences. Events include virtual 1x1 meetings at the Craig-Hallum Alpha Select Conference on November 16, a presentation at the Stifel 2021 Virtual Healthcare Conference on November 17 at 3:20 p.m. ET, and additional meetings at the Canaccord Genuity Forum on November 18. A fireside chat will be available on-demand at the Piper Sandler Conference starting November 22. Audio webcasts will be accessible on their investor relations website.
